<DOC>
	<DOCNO>NCT02026908</DOCNO>
	<brief_summary>This open-labeled , non-randomized feasibility study evaluate safety prostate artery embolization ( PAE ) treatment low urinary tract symptom attribute benign prostatic hyperplasia ( BPH ) .</brief_summary>
	<brief_title>Prostatic Artery Embolization ( PAE ) Treatment Benign Prostatic Hyperplasia ( BPH )</brief_title>
	<detailed_description>This pilot study single center , open label , non-randomized feasibility study evaluate initial safety PAE treatment symptomatic bladder outlet obstruction . 60 adult male subject enrol study . If eligible patient undergo prostate artery embolization procedure Interventional Radiology department . An angiogram prostate artery do . Small bead call Embospheres inject prostate artery slow blood flow prostate hope provide relief minimal side effect complication , low urinary tract symptom cause BPH . After procedure patient follow 4 week , 12 week , 6 month , 12 month post procedure annually 4 year .</detailed_description>
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<criteria>Diagnosis LUTS secondary BPH refractory to/contraindicated medical treatment . Ability understand willingness sign write informed consent Prostate volumes 40 200 gm . May include 3039 gm subject long history ineffective response combination medical treatment ( alphablocker 5alpha reductase inhibitor ) least 6 month Men ≥ 45 year age IPSS symptom score &gt; 13 IPSS bother score &gt; 2 Peak flow rate Qmax≤ 12 void volume ≥125 cc History prostate bladder cancer , pelvic radiation , untreated bladder stone , On alphablockers within past 2 week unless stable dose medication , stable urination pattern 2 week prior enrollment , willingness stay dose duration study , stop criterion meet 12 month f/u visit , or/part trial without catheter ( TWOC ) patient currently Acute Urinary Retention ( AUR ) On 5alpha reductase inhibitor within past 6 month unless stable dose medication stable urination pattern 30 day prior enrollment willingness stay dose duration study stop criterion meet 12 month f/u visit . On phenylephrine , pseudoephedrine , imipramine , anticholinergic cholinergic medication within past 2 week unless stable dose medication stable urination pattern 2 week prior enrollment willingness stay dose duration study stop criterion meet 12 month f/u visit . On estrogen , androgen , drug produce androgen suppression , anabolic steroid within past 4 month unless stable dose medication 30 day prior enrollment willingness stay dose duration study . Daily use pad device incontinence require . Urethral stricture , renal insufficiency ( i.e . creatinine &gt; 1.8 ) Known primary neurologic condition multiple sclerosis Parkinson 's disease neurological disease know affect bladder function . Neurogenic bladder , Hypotonic Bladder Prior treatment urinary incontinence Penile prosthesis . Artificial urinary sphincter . Documented bacterial prostatitis within past year . Active urinary tract infection ( UTI ) unless case regular catheter dependence think represent colonization . History chronic prostatitis within last 1 year Known bleeding disorder ( e.g . von willebrand disease ( VWD ) ) History urethral strictures/bladder neck closure ( BNC ) Prior prostate procedure ( e.g . Transurethral microwave therapy ( TUMT ) , transurethral needle ablation prostate ( TUNA ) , waterinduced thermotherapy ( WIT ) , transurethral resection prostate ( TURP ) , photovaporization prostate ( PVP ) ) Prior treatment overactive bladder ( e.g . intravesical botox ) Prostate Specific Antigen ( PSA ) &gt; 4.0 , &lt; 10.0 unless document negative prostate biopsy within past 2 year think harbor prostatic malignancy clinical opinion primary coinvestigator . Enrolled another treatment trial disease within past 30 day Declines unable provide inform consent Condition precluding catheterbased intervention ( ie occlude vessel , severe atheromatous disease ) Any serious medical condition likely impede successful completion study , certain mental disorder , uncontrolled diabetes , cardiac arrhythmia , cardiac disease include congestive heart failure , significant respiratory disease , know immunosuppression . A history rectal malignancy Prior surgical prostate intervention Interest future fertility Allergy Iodinated contrast agent responsive steroid premedication regimen Contraindication Conscious sedation</criteria>
	<gender>Male</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Prostate Artery Embolization</keyword>
	<keyword>PAE</keyword>
	<keyword>Benign Prostatic Hyperplasia</keyword>
	<keyword>BPH</keyword>
	<keyword>Lower Urinary Tract Symptoms</keyword>
	<keyword>LUTS</keyword>
</DOC>